European Patent for Treating Kidney Disease-Xort-GRANTED!Focused on developing innovative therapies to treat acute kidney disease, the Company has moved forward toward Phase 3 Trials to help with an orphan chronic kidney disease – Autosomal Dominant Polycystic Kidney Disease (ADPKD) and COVID-19 coronavirus acute kidney injuries. To date, the clinical stage programs have been designed to treat chronic ADPKD – XRx-008 and Acute Kidney Injury (AKI) associated with COVID-19 infection – XRx-101.
Xanthine oxidase inhibitors (XOI) have been reported to have a potent antiviral effect against influenza-A virus and herpes infections suggesting a potential therapeutic benefit for suppressing the COVID-19 infection.